Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bioventus (BVS) Equity Average (2021 - 2025)

Historic Equity Average for Bioventus (BVS) over the last 5 years, with Q3 2025 value amounting to $204.3 million.

  • Bioventus' Equity Average rose 868.83% to $204.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $204.3 million, marking a year-over-year increase of 868.83%. This contributed to the annual value of $203.4 million for FY2024, which is 3578.14% down from last year.
  • Per Bioventus' latest filing, its Equity Average stood at $204.3 million for Q3 2025, which was up 868.83% from $193.4 million recorded in Q2 2025.
  • Bioventus' 5-year Equity Average high stood at $564.8 million for Q2 2022, and its period low was $182.2 million during Q2 2021.
  • Moreover, its 5-year median value for Equity Average was $223.8 million (2023), whereas its average is $282.8 million.
  • Its Equity Average has fluctuated over the past 5 years, first surged by 20994.62% in 2022, then crashed by 5454.38% in 2023.
  • Bioventus' Equity Average (Quarter) stood at $419.1 million in 2021, then fell by 5.58% to $395.7 million in 2022, then crashed by 43.44% to $223.8 million in 2023, then decreased by 16.79% to $186.2 million in 2024, then increased by 9.7% to $204.3 million in 2025.
  • Its Equity Average stands at $204.3 million for Q3 2025, versus $193.4 million for Q2 2025 and $185.5 million for Q1 2025.